Model Lipid Raft Membranes for Embedding Integral Membrane Proteins: Reconstitution of HMG-CoA Reductase and Its Inhibition by Statins

被引:5
|
作者
Zaborowska, Michalina [1 ]
Matyszewska, Dorota [2 ]
Bilewicz, Renata [1 ]
机构
[1] Univ Warsaw, Fac Chem, PL-02093 Warsaw, Poland
[2] Univ Warsaw, Fac Chem, Biol & Chem Res Ctr, PL-02089 Warsaw, Poland
关键词
COENZYME-A REDUCTASE; AIR-WATER; CHOLESTEROL OXIDASE; CATALYTIC PORTION; DOMAIN; GRAMICIDIN; LIPOSOMES; LANGMUIR; CHANNEL; PROTEOLIPOSOMES;
D O I
10.1021/acs.langmuir.2c02115
中图分类号
O6 [化学];
学科分类号
0703 ;
摘要
For the first time, HMG-CoA reductase, the membrane protein responsible for cholesterol synthesis, was incorporated into a lipid membrane consisting of DOPC:Chol:SM at a 1:1:1 molar ratio, which mimics the lipid rafts of cell membranes. The membrane containing the protein was generated in the form of either a proteoliposomes or a film obtained by spreading the proteoliposomes at the air-water interface to prepare a protein-rich and stable lipid layer over time. The lipid vesicle parameters were characterized using dynamic light scattering (DLS) and fluorescence microscopy. The incorporation of HMG-CoA reductase was reflected in the increased size of the proteoliposomes compared to that of the empty liposomes of model rafts. Enzyme reconstitution was confirmed by measuring the activity of NADPH, which participates in the catalytic process. The thin lipid raft films formed by spreading liposomes and proteoliposomes at the air-water interface were investigated using the Langmuir technique. The activities of the HMG-CoA reductase films were preserved over time, and the two lipid raft systems, nanoparticles and films, were exposed to solutions of fluvastatin, a HMG-CoA reductase inhibitor commonly used in the treatment of hypercholesterolemia. Both lipid raft systems constructed were useful membrane models for the determination of reductase activity and for monitoring the statin inhibitory effects and may be used for investigating other integral membrane proteins during exposure to inhibitors/activators considered to be potential drugs.
引用
收藏
页码:13888 / 13897
页数:10
相关论文
共 41 条
  • [31] EFFECT OF A CHOLESTEROL DIET AND FURTHER SUPPRESSION ON THE LIPID-COMPOSITION AND HMG-COA REDUCTASE-ACTIVITY OF CHICK LIVER MICROSOMAL-MEMBRANES
    ALEJANDRE, MJ
    GARCIAGONZALEZ, M
    GONZALEZPACANOWSKA, D
    GARCIAPEREGRIN, E
    SEGOVIA, JL
    JOURNAL OF LIPID RESEARCH, 1986, 27 (05) : 558 - 558
  • [32] HMG-CoA reductase inhibition prior reperfusion improves reparative fibrosis post-myocardial infarction in a preclinical experimental model
    Vilahur, Gemma
    Casani, Laura
    Pena, Esther
    Juan-Babot, Oriol
    Mendieta, Guiomar
    Crespo, Javier
    Badimon, Lina
    INTERNATIONAL JOURNAL OF CARDIOLOGY, 2014, 175 (03) : 528 - 538
  • [33] ARTERIAL PLAQUE-FORMATION IN HYPERCHOLESTEROLEMIC RABBITS CORRELATES WITH CHANGES IN VASCULAR REACTIVITY AND LIPID PEROXIDE CONTENT - PREVENTION BY INHIBITION OF HMG-COA REDUCTASE
    GALLE, J
    BUSSE, R
    BASSENGE, E
    ARTERIOSCLEROSIS, 1990, 10 (05): : A834 - A835
  • [34] Inhibition of HMG-CoA reductase reduces secretion of large human apoB100-VLDL from a novel hepatic cell model
    Tran, K
    Song, DH
    Wang, YW
    Yao, ZM
    CIRCULATION, 1999, 100 (18) : 686 - 686
  • [35] Preservation of endothelial function by the HMG-CoA reductase inhibitor fluvastatin through its lipid-lowering independent antioxidant properties in atherosclerotic rabbits
    Mitani, H
    Egashira, K
    Ohashi, N
    Yoshikawa, M
    Niwa, S
    Nonomura, K
    Nakashima, A
    Kimura, M
    PHARMACOLOGY, 2003, 68 (03) : 121 - 130
  • [36] Inhibition of HMG-COA reductase activity with statins provides acute-g raft-versus-host disease protection by TH-2 cytokine induction while sparing graft-versus-leukemia activity
    Zeiser, R.
    Yotissef, S.
    Baker, I.
    Steinman, L.
    Negrin, R.
    BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2007, 13 (02) : 121 - 122
  • [37] Lipid-lowering drugs in the MPTP mouse model of Parkinson's disease:: Fenofibrate has a neuroprotective effect, whereas bezafibrate and HMG-CoA reductase inhibitors do not
    Kreisler, Alexandre
    Gele, Patrick
    Wiart, Jean-Francois
    Lhermitte, Michel
    Destee, Alain
    Bordet, Regis
    BRAIN RESEARCH, 2007, 1135 (01) : 77 - 84
  • [38] HMG-CoA reductase inhibitor pravastatin ameriolates left ventricular dysfunction through inhibition of oxidative stress and inflammation in a canine model of tachycardia-induced heart failure
    Nakamura, R
    Egashira, K
    CIRCULATION, 2001, 104 (17) : 247 - 247
  • [39] Fp9767Effects of HMG-CoA reductase inhibition on endothelial function and lipid profile in HIV-infected persons on protease inhibitor-containing antiretroviral combination therapy
    Hürlimann, D
    Chenevard, R
    Ruschitzka, F
    Enseleit, F
    Ledergerber, B
    Lüscher, TF
    Noll, G
    Weber, R
    EUROPEAN HEART JOURNAL, 2004, 25 : 145 - 146
  • [40] Angiotensin II type 1 receptor blockade elicits phospholipase a2-dependent beneficial effects on LDL-Oxidation beyond the lipid-lowering effects of a HMG-CoA reductase inhibition in patients with coronary artery disease
    Divchev, Dimitar
    Grothusen, Chistina
    Luchtefeld, Maren
    Drexler, Helmut
    Schieffer, Bernhard
    CIRCULATION, 2006, 114 (18) : 215 - 215